The potential rescheduling of cannabinoids, particularly at the federal level, is generating considerable buzz within the sector. A shift away from Schedule I status, often viewed as outdated and hindering innovation, could unlock significant possibilities for companies. Reduced regulatory burdens, alongside greater access to banking and capital, a